Track topics on Twitter Track topics that are important to you
EpimAb Biotherapeutics, a Shanghai bi-specifics company focused on cancer and immunotherapies, closed a $74 million Series B financing. The company uses its FIT-Ig® (Fabs-In-Tandem Immunoglobulin)...
EpimAb plans to use the funds to advance its Phase I/II clinical program, EMB01, expand its clinical pipeline into immuno-oncology and other areas and add a new manufacturing site in Suzhou for proces...
EpimAb Biotherapeutics Inc. (bispecific antibodies for cancer) raised $74mm through its Series B round co-led by new board members SDIC Fund and Sherpa Healthcare Partners. Also participating were SCV...
How EpimAb plans to use its $74M series B to accelerate its bispecific pipeline of immuno-oncology candidates.
Our CBO, Stephan Lensky, is presenting at the 26th @BioCentury #NewsMakers in #NYC on September 6. Stop by and reach out if you’re interested in a meeting! http://bit.ly
Funding to be used in growing and advancing the Company’s clinical pipeline of novel bispecific antibodies EpimAb Biotherapeutics, an emerging Shanghai-based biopharmaceutic...
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai with a proprietary and efficient technology called FIT-IgÂ® (Fabs-In-Tandem Immunogl...
EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technologyÂ called FIT-IgÂ® (Fabs-In-Tandem...
We have published hundreds of EpimAb news stories on BioPortfolio along with dozens of EpimAb Clinical Trials and PubMed Articles about EpimAb for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of EpimAb Companies in our database. You can also find out about relevant EpimAb Drugs and Medications on this site too.